Stockscreener 앱 받기
3.83
0.90%
-0.06
전일 마감가:
$3.89
열려 있는:
$3.84
하루 거래량:
109.94K
Relative Volume:
0.71
시가총액:
$309.97M
수익:
-
순이익/손실:
$-31.64M
주가수익비율:
-9.0629
EPS:
-0.4226
순현금흐름:
$-13.98M
1주 성능:
+6.20%
1개월 성능:
-2.90%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$3.80
$3.95
1주일 범위
$3.55
$3.95
52주 변동 폭
$3.51
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Compare NGEN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
3.83 | 314.82M | 0 | -31.64M | -13.98M | -0.4226 |
VRTX
Vertex Pharmaceuticals Inc
|
426.44 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
711.31 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.00 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.95 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.66 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nervgen Pharma Corp Stock (NGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-27 | 개시 | H.C. Wainwright | Buy |
Nervgen Pharma Corp 주식(NGEN)의 최신 뉴스
NervGen Pharma (NGEN) Stock Chart and Price History 2026 - MarketBeat
Top NervGen Pharma (NGEN) Competitors 2026 - MarketBeat
What is the current Price Target and Forecast for NERVGEN PHARMA (NGEN) - Zacks Investment Research
NERVGEN PHARMA (NGEN) - Zacks Investment Research
Biopharma Advances High-Impact, First-of-Its-Kind Neuroreparative Drug - Streetwise Reports
H.C. Wainwright reiterates NervGen stock rating on new CFO hire By Investing.com - Investing.com India
H.C. Wainwright reiterates NervGen stock rating on new CFO hire - Investing.com UK
EDGAR Filing Documents for 0001104659-26-049508 - SEC.gov
NervGen Pharma (NGEN) 10K Form and Latest SEC Filings 2026 - MarketBeat
NervGen Pharma (NGEN) Stock Trends and Sentiment 2026 - MarketBeat
NervGen Pharma Names New CFO and Wins Shareholder Backing for 2026 Equity Plan - TipRanks
NervGen appoints Keith Vendola as chief financial officer - Investing.com UK
NervGen Pharma (NGEN) Stock Forecast and Price Target 2026 - MarketBeat
NervGen Pharma initiated with a Buy at H.C. Wainwright - TipRanks
NervGen Pharma appoints Keith Vendola as CFO - TipRanks
NGEN Initiated Coverage by HC Wainwright & Co. -- Price Target A - GuruFocus
NervGen appoints Keith Vendola as chief financial officer By Investing.com - Investing.com Australia
This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer - The Manila Times
NervGen Pharma appoints new president & CEO - MSN
NervGen Pharma Corp. Common stock Stock Forecast Summary - Meyka
NervGen Pharma Corp. (NGEN) - Minichart
NervGen (NGEN) Stock Initiates Position (Near Lows) 2026-04-20Risk Analysis - UBND thành phố Hải Phòng
NervGen (NGEN) Stock: Why Short Sellers Target It (+1.19%) 2026-04-15Institutional Buying - Xã Vĩnh Công
NervGen's SCI Drug Shows 'Durable Improvement' in Chronic Injury - BriefGlance
NervGen Pharma initiated with a Buy at Lucid Capital - TipRanks
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference - Bitget
NervGen Pharma to Participate in the H.C. Wainwright - GlobeNewswire
NGEN Options Volatility — NASDAQ:NGEN - TradingView
NGEN Options Chain — NASDAQ:NGEN - TradingView
Is NervGen Pharma still undervalued? - Cantech Letter
Lobbying Update: $50,000 of NERVGEN PHARMA CORP. lobbying was just disclosed - Quiver Quantitative
NGEN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia - Sahm
NervGen receives FDA alignment on Phase 3 trial for tetraplegia By Investing.com - Investing.com South Africa
NervGen Pharma Says Phase 3 Chronic Tetraplegia Study Design Aligns With US FDA - marketscreener.com
NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia - TipRanks
NervGen receives FDA alignment on Phase 3 trial for tetraplegia - Investing.com
NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting - TipRanks
NervGen Pharma Corp. announces that patient enrollment for its Phase 1B/2a CONNECT-SCI clinical trial targeting individuals with quadriplegia due to subacute spinal cord injury is nearing completion. - Bitget
Nervgen Pharma announces successful end-of-phase 2 meeting and FDA alignment on Restore, a phase 3 registrational study of NVG-291 for chronic tetraplegia - marketscreener.com
Nervgen Pharma Announces Successful End-Of-Phase 2 Meeting And FDA Alignment On Restore, A Phase 3 Registrational Study Of Nvg-291 For Chronic Tetraplegia - TradingView — Track All Markets
FDA aligns on NervGen trial targeting hand use in tetraplegia - Stock Titan
NervGen Pharma Announces Successful End-of-Phase 2 Meeting - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: Milestone Scientific (MLSS) and NervGen Pharma (NGEN) - The Globe and Mail
The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight - The Manila Times
Nervgen Pharma Corp (NGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.78%
0.81%
자본화:
|
볼륨(24시간):